Academic Journal
Q2Oncology and Therapy
About Oncology and Therapy
Oncology and Therapy is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q2, with an SJR of 1.159 and H-index of 24.
Coverage: 2016-2026. Research categories: Oncology (Q2).
Verified field sources
- Journal Impact Factor: 3.4 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Lung Cancer Treatments and Mutations; Cancer Immunotherapy and Biomarkers; Cancer survivorship and care; HER2/EGFR in Cancer Research; Multiple Myeloma Research and Treatments; Lung Cancer Research Studies.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non–Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic Alterations
Dwight H. Owen, Martin Sebastian, Hirotsugu Kenmotsu, Shilpa Viswanathan et al.
2026-10-03 · DOI: 10.1007/s40487-026-00465-4Neoplasms Metastatic to the Larynx: A Systematic Review
Claudia Montenegro, Fatima-Ezzahra Nassih, Cesare Piazza, Alfio Ferlito et al.
2026-09-18 · DOI: 10.1007/s40487-026-00466-3Early-Onset Colorectal Cancer: Clinical and Molecular Features with Emerging Insights from Comprehensive Genomic Profiling
Amanda Nogueira, Jennifer Brondon, Konstantin Haradinov, Srinivasan Gopalakrishnan et al.
2026-09-16 · DOI: 10.1007/s40487-026-00467-2Real-World Testing Landscape and Costs of Companion Diagnostics and Comprehensive Genomic Profiling Across Nine Solid Tumors in Japan: A 10-Year Analysis
Kuniko Sunami, Sona-Sanae Aoyagi, Masashi Mikami, Kanae Togo et al.
2026-09-05 · DOI: 10.1007/s40487-026-00459-2A Qualitative Study of Patient and Caregiver Perspectives on Locally Advanced Head and Neck Cancer in the United States
Esther Yu, Veronica Ashton, OluYemisi Falope, Toby Hanna et al.
2026-09 · DOI: 10.1007/s40487-026-00464-5Patient-Reported Outcome Instruments in Non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review
Ingolf Griebsch, Sunil Shrestha, Carolyn C. Gotay, John L. Gore et al.
2026-09 · DOI: 10.1007/s40487-026-00463-6Exceptional Cure of a Patient with Progressive Advanced Squamous-Cell Lung Cancer after Selenite Treatment followed by Chemotherapy: A Case Report
Ola Brodin, Carlos Fernandez Moro, Mattias Hedman, Ozan Aricak et al.
2026-09 · DOI: 10.1007/s40487-026-00460-9Publisher Correction: Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial
Yuping Sun, Jia Zhong, Huiwen Sun, Graeme Parr et al.
2026-09 · DOI: 10.1007/s40487-026-00461-8Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial
Yuping Sun, Jia Zhong, Huiwen Sun, Graeme Parr et al.
2026-09 · DOI: 10.1007/s40487-026-00458-3Clinicians’ Perspectives on the Impact of Different Attributes of Androgen Receptor Pathway Inhibitors on Prostate Cancer Treatment Preferences and Compliance in Mexico
Mario Escobar Gómez, Ana Maria Rodríguez-Leboeuf, Selene Camargo-Correa, Ida Caterina García-Appendini et al.
2026-09 · DOI: 10.1007/s40487-026-00457-4A Comprehensive Mapping of Real-World Studies and Data Sources for Oncology in China: Insights into Landscape, Challenges, and Future Direction
Yaqi Jia, Yanbing Li, Siyan Zhan, Jeff Jianfei Guo et al.
2026-09 · DOI: 10.1007/s40487-026-00456-5IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
Sridevi Rajeeve, Saurabh P. Nagar, Sabyasachi Ghosh, Victoria Alegria et al.
2026-09 · DOI: 10.1007/s40487-026-00455-6Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape
Brian I. Rini, Benjamin Garmezy
2026-09 · DOI: 10.1007/s40487-026-00450-xGastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology
Celine Oanæs, Herish Garresori, Dordi Lea, Marcus T. T. Roalsø et al.
2026-09 · DOI: 10.1007/s40487-026-00454-7Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL
Daniel A. Ermann, Deborah M. Stephens, Xiaoliang Wang, Irene Varghese et al.
2026-09 · DOI: 10.1007/s40487-026-00452-9Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels
Paul Spin, Bela Bapat, Chad Moretz, Robert Dumanois et al.
2026-09 · DOI: 10.1007/s40487-026-00453-8Abemaciclib in HR+, HER2− Breast Cancer: A Narrative Review of the Clinical Evidence
Miguel Martin, Alexandru Rosca, Alexandra Searles Vitko, Monique Coersmeyer et al.
2026-09 · DOI: 10.1007/s40487-026-00449-4Evaluation of Drug–Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25)
Giandomenico Roviello, Mattia Alberto Di Civita, Daniele Santini, Elisabetta Gambale et al.
2026-09 · DOI: 10.1007/s40487-026-00448-5Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer
Michele Musone, Biagio Barone, Stefano Chianese, Paolo Conforti et al.
2026-09 · DOI: 10.1007/s40487-026-00445-8Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice
Patrick Squires, Ke Meng, Xiaohan Hu, Vladimir Turzhitsky et al.
2026-09 · DOI: 10.1007/s40487-026-00451-wReviews
Community Reviews
Version History
September 25, 2026 at 7:46 am
September 25, 2026